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atrial  ﬁbrillation:  Closing  the  door  to  hell
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Received  25  October  2012;  accepted  25  October  2012Atrial  ﬁbrillation  (AF)  is  one  of  the  most  challenging  arrhythmias  —  perhaps  even  one  of  the
most  challenging  diseases  —  because  of  its  high  prevalence  (close  to  2%  of  the  population
[1])  and  associated  risks  of  thromboembolism  and  stroke.  Stroke  is  a  devastating  complica-
tion  with  a  reported  annual  incidence  of  4.4%.  At  least  25%  of  the  130,000  strokes  that  occur
each  year  in  France  are  complications  of  AF.  For  patients  with  AF-related  cardioembolic
stroke,  up  to  70%  will  result  in  death  or  signiﬁcant  disability.
Prevention  of  thromboembolic  complications  in  AF  is  an  old  story  leading  to  clear  guide-
lines  and  robust  therapies.  The  CHADS2 score  [2]  and  more  recently  the  CHA2DS2VASc  score
[3]  were  developed  to  assess  stroke  risk  in  individuals  with  non-valvular  AF,  and  their  use
is  recommended  to  identify  patients  at  moderate  to  high-risk  of  stroke  but  also  to  identify
those  considered  truly  low-risk  [4].
Anticoagulation  therapy  with  vitamin  K  antagonists  (VKAs)  such  as  warfarin  has
remained  the  standard  of  care  for  stroke  prevention  in  AF.  Despite  clear  evidence  of
efﬁcacy,  the  limitations  of  VKAs,  including  potential  bleeding  complications  and  narrow
therapeutic  window,  have  resulted  in  poor  compliance  to  treatment,  low  rates  of  time-
in-therapeutic  range,  and  important  underutilization  in  patients  with  AF,  even  in  those
at  high-risk.  Antiplatelet  therapy  with  aspirin  has  low  efﬁcacy  compared  with  VKAs,  and
dual  antiplatelet  therapy  with  aspirin  and  clopidogrel,  despite  demonstrating  an  additional
effect,  has  not  matched  the  efﬁcacy  of  VKAs.
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he ﬁrst revolution in anticoagulation for
troke prevention
 number  of  large  randomized  studies  have  proved  the  efﬁ-
acy  of  several  new  oral  anticoagulants  for  prevention  of
hromboembolic  events  in  AF.  The  direct  thrombin  inhibitor
abigatran  [5,6]  and  the  factor  Xa  inhibitors  rivaroxaban
7]  and  apixaban  [6]  are  non-inferior  and  even  superior  to
arfarin  for  prevention  of  thromboembolic  events  in  non-
alvular  AF.  We  have  waited  a  long  time  for  the  advent  of
hese  new  drugs;  but  despite  their  indisputable  contribution
o  stroke  prevention  in  AF  not  all  of  the  problems  of  anti-
oagulation  have  been  solved,  leaving  both  clinicians  and
atients  still  facing  difﬁcult  choices:
a  large  proportion  of  patients  at  risk  of  stroke  or  systemic
embolism  remains  untreated  [8];
compliance  to  treatment  remains  problematic,  with
almost  one-quarter  of  patients  stopping  medication
within  2  years;
anticoagulation  is  a  life-long  treatment,  with  necessary
periods  of  interruption  (e.g.  for  a  surgical  intervention),
after  which  risk  of  thromboembolism  is  increased  [9];
contraindications  to  warfarin  are  frequent,  affecting
around  17%  of  the  AF  population;
treatment-associated  bleeding  still  exists;
the  combination  of  antiplatelet  and  oral  anticoagulant
therapy  dramatically  increases  risk  of  bleeding.
n alternative to anticoagulation:
cclusion of the left atrial appendage
n  non-valvular  AF  blood  stasis  in  the  left  atrium  is  the
ajor  mechanism  of  thrombus  formation,  with  clot  migra-
ion  in  the  cerebral  circulation  inducing  stroke.  The  left
trial  appendage  (LAA)  is  the  most  important  cardiac  source
f  thromboemboli  in  non-valvular  AF  [10], and  its  exclusion
hould  therefore  prevent  most  cases  of  thrombus  forma-
ion,  without  the  need  for  life-long  anticoagulation.  Based
n  this  hypothesis,  surgeons  widely  perform  LAA  appendage
xclusion  as  a  concomitant  procedure  during  open-heart
urgery  and  several  systems  for  percutaneous  occlusion  of
he  LLA  have  been  developed.  The  randomized  Watchman
eft  Atrial  Appendage  System  for  Embolic  Protection  in
atients  With  AF  (PROTECT-AF  [11]) trial  demonstrated  the
alidity  of  the  concept  and  the  therapeutic  non-inferiority
f  LAA  closure  as  an  alternative  to  long-term  warfarin  treat-
ent  in  preventing  stroke  in  non-valvular  AF  patients  with  a
HADS2 score  ≥  1.  The  primary  composite  efﬁcacy  endpoint
as  stroke,  systemic  embolism  and  cardiovascular  death.
atients  randomized  to  the  LAA  closure  strategy  had  a  lower
vent  rate  than  those  randomized  to  warfarin  (3.0  vs.  4.9  per
00  patient-years,  respectively),  with  a  relative  rate  ratio  of
.62  (95%  conﬁdence  interval  0.35—1.25),  which  translated
o  non-inferiority  of  the  LAA  closure  strategy  to  warfarin
reatment.
Even  if  the  ﬁndings  are  extremely  debatable,  a  sys-
ematic  review  of  eight  prospective  non-comparative
bservational  studies  with  the  different  systems  of  percu-
aneous  LLA  occlusion  has  estimated  the  annual  stroke  risk
ased  on  historical  controls  and  CHADS2 score.  This  compar-
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son  indicated  an  overall  stroke  reduction  from  1.9—8.6%  to
—3.8%  in  respective  studies  [12].
evice and procedure description
n  2006  the  manufacturer  of  Percutaneous  Left  Atrial
ppendage  Transcatheter  Occlusion  (PLAATO)  —  the  ﬁrst
evice  to  be  developed  for  percutaneous  LAA  occlusion
PLAAO)  —  discontinued  product  development  despite  two
rospective  multicentre  observational  studies  suggesting
he  feasibility  of  this  technique  with  an  acceptable  risk
13].  Two  devices  —WatchmanTM (Boston  Scientiﬁc,  Natick,
A,  USA)  and  Amplatzer  Vascular  PlugTM (Saint-Jude  Medi-
al,  Saint-Paul,  MN,  USA)  —  are  currently  available  in  clinical
ractice  and  a  third  is  in  development.
The  LAA  occlusion  implantation  must  be  performed  in
entres  with  cardiac  surgical  facilities.  The  implanter  must
e  experienced  or  have  received  speciﬁc  training.  The  pro-
edure  is  performed  under  transesophageal  echocardiogram
TOE)  control,  requiring  a  general  anaesthesia.  A  sheath
s  introduced  into  the  right  femoral  vein.  Access  to  the
eft  atrium  takes  place  via  a  transseptal  puncture.  After
pproximating  the  size  and  shape  of  the  LAA  under  TOE  or
uoroscopic  guidance,  the  device  is  sized  using  a  standard-
zed  chart  and  is  then  advanced  into  the  LAA  oriﬁce.  Imaging
s  used  to  conﬁrm  optimal  positioning  before  the  device  is
eleased  and  the  delivery  system  withdrawn  into  the  right
trium.  To  avoid  thrombus  formation  and  stroke  during  the
rocedure  strong  anticoagulation  with  low-molecular  weight
eparin  is  performed  to  reach  an  activated  clotting  time  of
50—350  seconds.
In  PROTECT-AF,  warfarin  was  administrated  for  at  least
5  days  after  device  implantation  to  avoid  excessive  throm-
us  formation  on  the  device,  until  device  endothelialization
upervened.  In  the  ASA  and  Plavix  (ASAP)  study,  involving
50  patients  contraindicated  to  warfarin,  post-procedural
nticoagulation  was  replaced  by  an  antiplatelet  regimen
ith  clopidogrel  up  to  6  months  and  aspirin  indeﬁnitely.  An
ntiplatelet  regiment  is  also  used  after  Amplatzer  device
mplantation.  Follow-up  TOE  imaging  was  performed  to
ssess  for  device  stability,  peridevice  leaks  and  device-
elated  thrombus.
afety concern
eriprocedural  complications  must  be  taken  into  account
nd  balanced  against  the  risks  of  long-term  anticoagula-
ion.  Transseptal  puncture  occasionally  occurs  in  patients
ith  very  large  atria;  manipulation  of  ‘complex’  material,
ometimes  with  various  sheaths,  within  the  atria  and  par-
icularly  within  the  thin  LAA  can  be  a  challenging  and  risky
rocedure.  In  a  recent  review  of  the  major  studies  and  reg-
stries,  periprocedural  death  occurred  in  ﬁve  patients,  with
n  overall  rate  of  1.1%.  Pericardial  effusion/cardiac  tam-
onade  was  the  most  frequent  procedure-related  adverse
vent:  6.5%  in  PROTECT-AF  [11]  and  4.1%  among  all  studies
eported.  Pericardial  effusion  was  the  primary  reason  for
rgent  cardiac  surgery.  Periprocedural  device  embolization
ccurred  in  0.7%  of  the  implanted  patients.  Some  occurred
uring  the  procedure  but  several  were  discovered  at  the  ﬁrst
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approach: the Euro Heart Survey on atrial ﬁbrillation. ChestLeft  atrial  appendage  occlusion  for  prevention  of  thromboem
echocardiographic  control.  Per-procedural  stroke  occurred
in  0.6%  of  cases  and  in  several  was  due  to  air  embolism.  In
PROTECT-AF  three  of  ﬁve  strokes  were  air  embolisms.  Clot
formations  on  the  implanted  device,  without  embolization
but  requiring  modiﬁcation  of  anticoagulation  management,
have  also  been  reported.
The  complication  rate  is  strongly  inﬂuenced  by  opera-
tor  experience.  In  PROTECT-AF  the  rate  decreased  between
the  early  and  late  phases,  and  continued  to  decrease,  as
shown  by  data  from  the  Continued  Access  Protocol  (CAP)
registry  [14]. The  implant  success  rate  in  CAP  improved
from  91%  to  95%  (P  =  0.033),  while  the  rate  of  pericardial
effusion  decreased  from  4.1%  to  2.2%,  with  no  strokes.  The
overall  procedure-  or  device-related  safety  adverse  events
within  7  days  decreased  from  6.5%  in  PROTECT-AF  to  3.7%
in  the  CAP  registry  (P  =  0.061).  Fewer  data  are  available
for  the  Amplatzer  plug,  but  a  recent  registry  [15]  reported
10/137  (7%)  severe  complications  of  which  three  (2%)  were
ischaemic  strokes,  two  (1.4%)  were  device  embolizations
and  ﬁve  (3.6%)  were  signiﬁcant  pericardial  effusions.  The
effect  of  operator  experience  is  also  clear,  with  most  of  the
complications  occurring  in  the  ﬁrst  patients  implanted  in
the  centres,  highlighting  the  need  to  perform  these  implan-
tations  in  centres  with  cardiac  surgical  facilities,  sufﬁcient
volume  of  implantations  and  comprehensive  operator  train-
ing.
Which patients should undergo
percutaneous left atrial appendage
occlusion?
Strong  trial  evidence  is  available  to  support  anticoagulation
as  the  ﬁrst-line  therapy  for  prevention  of  thromboembolism
in  AF.  The  latest  European  Society  of  Cardiology  (ESC)  recom-
mendations  are  clear:  ‘Although  the  concept  of  LAA  closure
seems  reasonable,  the  evidence  of  efﬁcacy  and  safety  is
currently  insufﬁcient  to  recommend  these  approaches  for
any  patients  other  than  those  in  whom  long-term  OAC  is
contraindicated.  Additional,  adequately  powered,  random-
ized  studies  in  patients  with  high  stroke  risk  and  long-term
follow-up,  comparing  interventional/percutaneous/surgical
LAA  closure  with  [oral  anticoagulant]  therapy  including
novel  oral  anticoagulant  drugs,  are  needed  for  adequate
assessment  of  such  techniques’  PLAAO  may  be  considered
in  patients  with  a  high  stroke  risk  and  contraindications
for  long-term  oral  anticoagulation  (Class  IIb,  Level  B)  [4].
But  what  is  a  contraindication  for  long-term  oral  anticoagu-
lation?  Several  proposals  are  listed  in  AVERROES  [16]  and
ACTIVE  A,  many  of  which  are  debatable  or  practitioner-
dependent.
The  indication  for  LAA  occlusion  retained  in  the  ESC
guidelines  is  not  the  indication  of  the  single  randomized
study  with  PLAAO,  but  is  the  ﬁrst  indication  in  clinical
practice.  In  the  European  registry  with  the  Amplatzer  plug
[15],  78.9%  of  indications  for  PLAAO  were  due  to  high
bleeding  risk,  8.9%  to  haemorrhagic  history  and  11.3%  to
stroke  under  anticoagulation.  Even  if  these  populations  are
probably  the  most  logical,  caution  must  be  exercised.  Haem-
orrhagic  risk  increases  with  age,  comorbidity  and  CHADS2
score.  The  CHADS2 score  was  2.4  in  the  Amplatzer  plugic  events  621
uropean  registry  and  2.8  in  the  ASAP  study,  versus  2.2
n  PROTECT-AF.  Patients  with  a  contraindication  to  anti-
oagulation  are  sicker  than  those  without,  with  several
ossible  consequences  in  favour  of  anticoagulation  rather
han  PLAAO:
the  risk  of  complications  during  the  procedure  may  be
higher  in  this  population;
in addition  to  the  risk  of  stroke  due  to  stasis  within  the
left  atria,  other  mechanisms  and  origins  of  stroke  could
be  higher  in  this  population,  increasing  with  the  presence
of  a  comorbidity;
a recent  publication  has  shown  that  absence  of  antico-
agulation,  left  ventricular  dysfunction  or  prior  stroke  is
associated  with  a  higher  proportion  of  extra  LLA  thrombi
[17].
Based  on  the  above  indications  for  PLAAO,  most  such
ases  will  be  difﬁcult,  with  several  possible  solutions.  The
ndication  for  LLA  closure  must  therefore  be  based  on  a
ultidisciplinary  decision  involving,  for  example,  the  neu-
ologist,  neurosurgeon  or  gastroenterologist.  At  the  same
ime  the  therapeutic  management  of  AF  should  be  discussed,
uch  as  ablation  following  device  implantation.
onclusion
troke  must  be  prevented  in  high-risk  patients  with  AF.  Anti-
oagulation  remains  the  ﬁrst-line  therapy,  but  when  this
pproach  is  contraindicated  or  associated  with  a  high-risk
f  bleeding,  other  solutions  must  be  considered  to  avoid  the
otentially  devastating  consequences  of  an  embolic  event.
LAAO  has  a  strong  rationale  and  encouraging  data  exist  to
how  the  feasibility  of  such  an  approach,  with  an  acceptable
isk  if  undertaken  in  experienced  centres.  While  further
esearch  into  this  therapeutic  option  is  clearly  necessary,
LAAO  may,  for  some  patients,  offer  a way  of  closing  the
oor  to  hell.
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